- ASX: MPL
Medibank Private Ltd
ASX BIG FOUR - LIVE SNAPSHOT
Whitehaven Coal
(ASX:WHC)
Elixir Energy
(ASX:EXR)
Aspen Group
(ASX:APZ)
Lovisa
(ASX:LOV)
About Medibank Private Ltd
Medibank Private's Company History
- Free Report
Get Our Full ASX Stock Analysis Report
Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.
Medibank's Outlook
Medibank has well and truly recovered from the cyber attack and is recording policyholder growth, particularly amongst those taking out cover for the first time. Nonetheless, Medibank has new issues it had to address. The company faces intense competition from rivals that offer cheaper policies. There are calls from struggling private hospitals to get insurers (particularly larger, profitable companies) to put more money into the healthcare systems – a potential lose-lose situation for the company because it could lose members in a cost of living crisis. The 2025 collapse of Healthscope showed that the calls private hospitals were struggling were not sensationalists. Medibank agreed to take ‘soft’ steps including out-of-cycle funding for private hospitals operators, but this did not save Healthscope. FY25 saw $8.6bn in total revenue, up 5.2%, and a $618.7m post-tax profit on an underlying basis, up 8.5%. A total of $6.6bn in claims were paid and there was 1.4% growth in net resident policyholders and 3.1% growth in non-resident policy units. For FY26, the company guided to claims per policy unit growth of 2.6-2.9%. But moderating of industry growth was anticipated and policyholder growth would be grown ‘in a disciplined way’.
Is Medibank Private a Good Stock to Buy?
We think it has potential. It is a consistent dividend payer and has a track record of policyholder growth ever since it listed on the ASX. Medibank is often viewed as a defensive stock because demand for health insurance tends to be relatively stable compared with more cyclical industries. But earnings can still be affected by regulatory changes, claims inflation and competition.
Related Articles
SK hynix (NSDQ:SKHY) Surges 27% as Investors Reprice Its 58% HBM Leadership
Vection (ASX:VR1) locks in A$7.5m URBANnext framework as channel strategy takes shape
SK Hynix Crashed 15% Days After Its Record Debut: Is the AI Memory Trade Cracking?
The AI Chip Trade Faces a Key Test This Week: What TSMC’s Results Mean for Nvidia and AMD
DeepSeek Is Building Its Own AI Chip: Is This a Real Threat to Nvidia?
Frequently Asked Questions
What is Medibank Private Limited?
How did Medibank evolve since its inception?
What makes Medibank stand out in the health insurance market?
What were the financial impacts of the 2022 cyber attack on Medibank?
Is Medibank a good investment choice?
Stay Sharp on the ASX
Weekly research. Independent analysis. No noise.
Free forever · Unsubscribe anytime
